BofA raised the firm’s price target on Alkermes to $33 from $30 and keeps a Neutral rating on the shares. Based on FY24 guidance that calls for lower operating expenses than the firm previously assumed, it is raising 2024 and FY25 non-GAAP EPS estimates by 12% and 13%, respectively, while it also made “small tweaks” to its topline forecast. However, the firm notes it made “no major changes” to its sales forecasts for Alkermes’ key proprietary products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALKS: